Grifols, S.A.
https://www.grifols.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Grifols, S.A.
Deal Watch: Adaptimmune, TCR2 Join Forces As Cell Therapy Company Focused On Solid Tumors
All-stock merger will create new company owned 75% by Adaptimmune’s shareholders. Grifols, Selagine to explore antibody approach to treating dry eye disease, and other recent deals.
Spain’s Grifols Takes Restructuring Route After COVID Challenges
The Barcelona-based company is making major cuts to its headcount in a bid to save €400m and support its operational recovery after the significant impact of the pandemic to Grifol’s plasma business.
Leo Pharma Strengthens Dermatology Position With Second Eczema Win
The company reported positive topline results from a second trial of its topical pan-JAK inhibitor, delgocitinib, in chronic hand eczema.
Scrip Asks…What Does 2023 Hold For Biopharma? Part 6: Artificial Intelligence
The biopharma industry may not have been the fastest adopter of artificial intelligence, but its vast potential means companies of every shape and size know they cannot ignore it. Executives, advisors and investors share their predictions around the impact of AI in 2023.
Company Information
- Industry
- Pharmaceuticals
-
Medical Devices
- Diagnostic Equipment & Supplies
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Other Names / Subsidiaries
-
- Alpha Therapeutic Corporation
- Biotest AG
- Goetech LLC
- GigaGen, Inc.
- Grifols Therapeutics, Inc.
- MedKeeper
- Talecris Biotherapeutics Inc.
- Haema AG.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice